

Obstetrics & Gynecology NEWSLETTER

SCIENCE FEATURE:

Dr. Elizabeth Hopp Principal Investigator of an NRG clinical trial

Adult Granulosa Cell Tumors (AGCT) are such a rare cancer type, there is currently a lack of prospective trials available to provide the best, evidence-based treatment for patients with advanced or recurrent disease and limited treatment options overall. Elizabeth Hopp, MD, a Gynecologic Oncologist at the Medical College of Wisconsin is the Principal Investigator of a new trial, NRG-GY033—MCT060169124.

This is a Phase II Study of Androgen Receptor (AR) Inhibition by Darolutamide in Combination with Leuprolide Acetate and Exemestane in Recurrent Adult-Type Ovarian Granulosa Cell Tumor. Adult-type ovarian granulosa cell tumors (AGCT) are characterized by hormonal excess and a pathognomonic missense mutation in the FOXL2 gene. This mutation is thought to stimulate transcription of hormones leading to increased androgen and estrogen expression. A series study had MCW showed 6 out of 7 patients received clinical benefit with minimal toxicity. The NRG study is actively enrolling patients.

GRANT HIGHLIGHTS

Akinyemi Ojesina, MD, PhD: *National Cancer Institute (NCI) - 1U54HD113408—Molecular Markers for Tumors Associated with Extrachromosomal HPV*

Dr. Ojesina's NIH grant involves work which will be impactful for cervical cancer diagnosis and treatment. It is well known that human papillomaviruses (HPV) cause cervical cancer by inserting into human DNA (a process called viral integration) and creating instructions for the infected cells to grow more rapidly than normal cells. Dr. Ojesina and his team have identified a subset of cervical cancers in which HPV is present but not integrated into human DNA. In this project, they will identify the molecular mechanisms by which cervical cancer develops in the absence of HPV integration and leverage these insights to create a diagnostic test that will help to better streamline patients for effective targeted therapy. They will also investigate the effectiveness of novel therapies for cervical cancer.


NEW GRANTS:

- **Akinyemi Ojesina, MD, PhD:** *National Cancer Institute (NCI) - 1R01CA279323 —Molecular Markers for Tumors Associated with Extrachromosomal HPV*
- **Stephanie Gunderson, MD:** *Advancing Healthier Wisconsin (AHW) - Increasing Equitable Access to Fertility Preservation Care in AYAs with a New Cancer Diagnosis*
- **Elizabeth Hopp, MD:** *MCW Cancer Center - Identification of Targeted Treatments for Adult-Type Granulosa Cell Tumors of the Ovary (AGCT) through In-depth Multi-omics Analysis*
- **Mona Singh, PhD:** *Ovarian Cancer Research Alliance - Unexplored role of specific subpopulation B cells in the ovarian cancer microenvironment*

GRANT HIGHLIGHTS CONT'D

RESEARCH FEATURE:

Stephanie Gunderson, MD has been hard at work advocating for and improving the fertility preservation process here at F&MCW. Dr. Gunderson has received a **AHW seed grant “Increasing Equitable Access to Fertility Preservation Care in AYAs with a New Cancer Diagnosis”**. This grant will allow Dr. Gunderson and her team the ability to track fertility preservation referrals as well as understand which providers are not referring patients in an attempt to unveil biases and barriers that exist with the fertility preservation referral process. Dr. Gunderson hopes that this work will inform tailored education tools for clinicians regarding fertility preservation services as well as increase patient satisfaction with their care as many studies have shown that having a fertility preservation discussion with clinicians is a major care satisfier for patients with a new cancer diagnosis. Dr. Gunderson, in the past four years, has increased fertility preservation referrals and procedures being complete and has also recently completed F&MCW first main operating room egg retrieval for a patient who otherwise would not have had the opportunity to preserve their fertility at F&MCW. Dr. Gunderson’s passion for fertility preservation is admirable and we look forward to her future progress in her endeavors.

**OBGYN VICE CHAIR OF CLINICAL RESEARCH**

Dr. Anna Palatnik started at the Medical College of Wisconsin in 2016 after completing a fellowship in Maternal-Fetal-Medicine at Northwestern University in Chicago. She is a clinician-scientist and the Patrick J. and Margaret G. McMahon Endowed Chair and an Associate Professor in the Department of Obstetrics and Gynecology. Dr. Palatnik’s research focuses on optimizing management of gestational diabetes and hypertensive disorders of pregnancy, reducing maternal health disparities, and improving health outcomes for birthing people during and after pregnancy. Dr. Palatnik runs a large clinical Maternal Fetal Medicine research program in the Department and is the primary investigator for several NIH and industry funded clinical trials involving birthing people. Dr. Palatnik has over 100 peer-reviewed publications in clinical obstetrics and patient-centered outcomes research. She is passionate about mentoring and training the next generation of clinician-researchers and close to half of her publications have a mentee or trainee as a first author.



Dr. William Bradley started at the Medical College in 2008 after completing a fellowship in Gynecologic Oncology at Mount Sinai Medical Center in New York City. Through his leadership the clinical trials program in the Division of Gynecologic Oncology moved from an affiliate site with limited clinical trial options, to a robust program, offering treatment options for developing therapies in all gynecologic cancers. He is actively involved at a national level with the GOG Foundation as a member of the investigators counsel, and with NRG Oncology as a member of the Developmental Therapeutics and Phase I groups. At MCW he is in the Phase I Disease Orientated Team (DOT) in the Cancer Center and actively collaborates with clinical and basic science faculty to develop new research opportunities. He has received funding from the NIH and industry and his work is exemplified by co-authorship in two publications in the New England Journal of Medicine on the use of PARP inhibitors in ovarian cancer. He has recently served on grant review boards for the DOD and the VA, as well as advising on developing therapies with industry.



RANDOMIZED CONTROL TRIAL HIGHLIGHT:

Preventing Common Obstetric Complications Through an Immersive Medically Tailored Meal Program (PLATE)

—PI: Anna Palatnik, MD

PLATE is out of the Advancing Healthier Wisconsin (AHW) Food For Healthier Birth Outcomes Grant that was awarded at the end of 2023.

This study is in partnership with Food for Health, a local non-profit, looking at addressing gaps in food insecurity amongst Milwaukee County residents. Preventing Common Obstetric Complications Through an Immersive Medically Tailored Meal Program (PLATE) is a pilot RCT where individuals at risk of developing GDM or HDPs are randomized to one of two groups. The intervention will have access to 10 fresh, local meals delivered to their home weekly, as well as weekly coaching sessions from Food for Health coaching staff, in addition to their standard of care, while the control group will continue with the standard of care.

NEW CLINICAL TRIALS:

- **PI: Elizabeth Hopp, MD — NRG-GY033:** A Phase II Study of Androgen Receptor (AR) Inhibition by Darolutamide in Combination with Leuprolide Acetate and Exemestane in Recurrent Adult-Type Ovarian Granulosa Cell Tumor. This study is being done to answer how well does the drug combination of darolutamide, leuprolide acetate, and exemestane work in treating your type of recurrent cancer.
- **PI: William H. Bradley— NRG-GY031:** A phase Ib trial tests the safety, side effects, and best dose of M1774 when given with ZEN-3694 in treating patients with ovarian and endometrial cancer that has come back (recurrent). M1774 and ZEN-3694 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. M1774 and ZEN-3694 combined together has demonstrated to be better than either drug alone in killing ovarian tumor cells in earlier study. Part II of the study will focus on treating patients with intact or loss ARID1A in Recurrent Ovarian and Endometrial Cancer.
- **PI: Denise Uyar, MD— SUTRO-STRO-002-GM2:** A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRa) Antibody Drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers). In this study, we want to find out more about the side effects (problems and symptoms) of an experimental drug for cancer, STRO-002, in combination with an approved drug, bevacizumab, and what doses of STRO-002 and bevacizumab together are safe for people to take.

WELCOME FACULTY:

Erica McKinney, PhD —Assistant Professor in OBGYN psychology for perinatal mental health, division of REI, joining us from University of Georgia.



Delaney Halpin, MD — Assistant Professor in General Obstetrics & Gynecology, joining us from University of Toledo College of Medicine & Life Sciences.



Salma Aljamal, MD — Assistant Professor in General Obstetrics & Gynecology, joining us from Advocate Aurora Medical Center.



Sonia (Sofia) Gabrilovich, MD — Assistant Professor in Gynecologic Oncology, joining us from University of Iowa.



Rosinda De La Pena, MD — Assistant Professor in Maternal-Fetal Medicine joining us from our MFM Fellowship program.



Jennifer Gassner, MD — Assistant Professor in General Obstetrics & Gynecology, joining us from Care New England Medical Group, Pawtucket, RI.




Laura Haworth, MD, MSW, MPH — Assistant Professor in Complex Gynecology joining us from Eastern Virginia Medical School.



Brock Polnaszek, MD — Assistant Professor in Maternal-Fetal Medicine, joining us from Warren Alpert Medical School of Brown University.



Natalie Mironov, DO — Assistant Professor in General Obstetrics & Gynecology, joining us from Beaumont Hospital.



Aref Senno, MD — Assistant Professor in General Obstetrics & Gynecology, joining us from University of Pennsylvania—Pennsylvania Hospital.

WELCOME APCs:

Karli McManaman, NP —Nurse Practitioner in REI, joining us from Florida Reproductive Associates.



Marisa Abbinanti, CNM — Certified Nurse Midwife in General Obstetrics & Gynecology, joining us from Ascension Columbia St. Mary's Hospital



Elizabeth (Liz) Collis, CNM — Certified Nurse Midwife in General Obstetrics & Gynecology, joining us from Prevea Health-OB/GYN Clinic and HSHS St. Nicholas-Birth Center.



Tracy Lemmer, CNM — Certified Nurse Midwife in General Obstetrics & Gynecology, joining us from Aurora Midtown Health Center.

WELCOME STAFF PHYSICIANS:

Ashley Wanless, MD —Physician in General Obstetrics & Gynecology, 2011 OBGYN Resident Alum, joining us from Froedtert Menomonee Falls Hospital.



Amy Dielstelhorst, MD — Physician in General Obstetrics & Gynecology, joining us from Froedtert Menomonee Falls Hospital.

Faculty Promotions:

- **Allison Linton, MD** — Associate Professor
- **Emily Davidson, MD** — Associate Professor
- **Mona Farez, MD**— Associate Professor

Celebration of Employees:

- **Marissa Iden, PhD** —10 years
- **Jamie Neary, NP**—10 years
- **Alison La Pean Kirschner, CGC**—10 years
- **Amy Cain, NP** —5 years
- **Jasmine George, PhD** —5 years
- **Erica Marion, PhD** —5 years
- **Kristen Streitenberger, PA-C** —5 years
- **Sarah Zablocki** —5 years

Thank you Carol Eling, APNP! Carol Eling has been a wonderful member of our team since 2019. Carol has more than 23 years of women's health and fertility experience.

In her care for patients, Carol focused on the whole-couple's story and provided compassionate, evidence-based care. She believed in the power of the women she cared for. Carol has been a great member of our team, and we will miss her! We are grateful for her friendship, teamwork, and care for patients.

WELCOME NEW STAFF:

Nancy Peret, RN — GynOnc Research Nurse with our Clinical Trials.



Rameesa Darul Amne Syed Mohammed, PhD —Postdoctoral Fellow in Dr. Rader's Lab.



Jessica Schultz — Maternal-Fetal Medicine Research Coordinator.



Arezou Rahimi, PhD — Postdoctoral Fellow in Dr. Sunila Pradeep's Lab.



Theresa Dlugi, PhD— Research Associate in Dr. Janet Rader's Lab.



Goyla Shahroki, PhD — Postdoctoral Fellow in Dr. Akinyemi Ojesina's Lab.



Mychaela Moore — GynOnc Research Coordinator with our Clinical Trials.

✓ MARK YOUR CALENDARS:

October 9, 2024: Eleanor Delfs, MD
Lectureship for Pioneers

Louis J. Muglia, MD, PhD— “The Time to be Born”
 President and CEO of the Burroughs Wellcome Fund
 Previously, he served as Vice Chair for Research, Director of the Division of Human Genetics, Co-Director of the Perinatal Institute, and Professor of Pediatrics at Cincinnati Children’s Hospital Medical Center.

April 11, 2025: Annual Women’s Health Conference

More details to come. Please save the date!



To support our department in research or education, visit our website at <https://obgyn.mcw.edu/about-us/philanthropy/> or call (414) 955-4711 to donate.

DEPARTMENT NEWS


- **Elizabeth Hopp, MD, GynOnc** Physician, awarded MCW Cancer Center pilot funding to improve outcomes for patients with rare ovarian cancer.
- **Jessica Chung, MD, MFM Fellow**, received Queenan Global Health Fellowship award for 2024.
- **Erin Bishop, MD** spoke about cervical cancer at the Lazos de Esperanza Symposium.
- MCW OBGYN Senior Student Awards went to Kaila Harold and Leah Gerlach
- **Rosinda De La Pena, MD**, received the MCW Outstanding Medical Student Teacher award.



Franklin High school student, Vaidehi Ramachandrupa, has been raising funds for ovarian cancer by dancing. She has raised nearly \$4,000. Look for communication on her next event.

Philanthropy Corner:

Ray of Hope for Ovarian Cancer Cure is a non-profit organization established in 2018 with a mission to bring together researchers, nurses, doctors, and community members impacted by ovarian cancer to celebrate triumphs, share losses, and raise funds for advanced research. This organization has supported our Women’s Health Research Program for over 4 years and has been wonderful partners to us. Each year, Ray of Hope hosts a run that brings together community members to raise awareness and funds to support ovarian cancer research.



GENETIC COUNSELOR NEWS:

- Ellen Saurer obtained her masters degree in Genetic Counseling through Baypath University and is now practicing at Ohio Health in Columbus, Ohio. During her training, she was a genetic counselor assistant with us for 4 years working with our prenatal and our subspecialty group. 
- Kayla Gotzion started 6/3/24. Kayla Gotzion, BS, will be our new full-time NICHE/AGMC GCA, replacing Ellen. She is coming in with many experiences that translate well to this position. Her most recent position has been with UnityPoint Health (Madison) as a Health Unit Coordinator for their NICU. 
- **Meredith Cruz, MD; Rosinda de la Pena, MD; Robert Rydze, MD; Seema Menon, MD; Maria Brix, MD ('26); Emily Davidson, MD; Mitchell Depke, MD ('26); Paul Lemen, MD; Allision Linton, MD; Katherine Lukas, MD ('25); Michael Lund, MD; Emily Smith, MD; Alina Tvina, MD; Kristina Kaljo, PhD** were all recipients of the 2022-2023 Teacher Recognition Pins for outstanding medical school teachers.

**Stay in touch and
follow us!
Have something to share?
Send it our way!**

DEPARTMENT NEWS Cont'd:

- **Abbey Kruper, PsyD, ABPP** - Clinical Health Psychologist, now certified as American Board of Professional Psychology (ABPP)
- **Janet S. Rader, MD** is now Associate Director, CRTEC Medical College of Wisconsin Cancer Center
- **Kristina Kaljo, PhD** has been named Vice Chair of Education in the Department of Obstetrics & Gynecology
- The Word on Medicine hosted **Dr. Emily Davidson**, GERALYN Schuster (RN, WISH nurse) and two grateful patients, discussing Pelvic Organ Prolapse in April.
- **Drs. Denise Uyar, William Bradley, Elizabeth Hopp**, and Beth Erickson - are joined by two patients that share their stories on Cervical Cancer hosted on The Word on Medicine in January.
- Secondary Faculty, **Dr. Stephanie Olivier-Van Stichelen**, discusses artificial sweeteners and non-nutritive sweeteners and its potential risks on fetal development on WTMJ radio.
- **Morgan Briggs, MD**, received the Association of Professors of Gynecology and Obstetrics (APGO) Humanism in Teaching Award.
- **Kristina Kaljo, PhD**—Recipient of the inaugural Campbell Fund for Narrative Medicine award (\$50,000 faculty award).

WELCOME RESIDENT CLASS OF 2028:



Alexander Choi, MD
University of Iowa -Ray &
Lucille Carver College



Leah Gerlach, MD
Medical College of
Wisconsin



Kristen Lentsch, MD
Indiana University School
of Medicine



Monica Myers, MD
Chicago Medical School -
Rosalind Franklin



Kathryn Tighe, MD
Western Michigan Univ.-
Homer Stryker MD

WELCOME NEW FELLOWS:



Catherine Bachur, MD— MFM
Fellow from Lewis Katz School of
Medicine at Temple University



Sarah McDonald, MD—GynOnc
Fellow from Medical University of
South Carolina



Kristin Dowe, PhD —Postdoctoral
Psychology Fellow from University
of Wisconsin – Madison

PSYCHOLOGY EDUCATION NEWS:

We are excited to announce a new fellowship in Psychology this year. Kristin Dowe will be working closely with our perinatal patients in both the outpatient and inpatient settings, as well as collaborating on research and educational initiatives.



Dr. Anna Palatnik, MD,
2009 OBGYN resident
alum, joining **Raj Narayan, MD,** Associate Dean
for Student Affairs, hood-
ing and commencement
ceremony.

ALUMNI CORNER:

We'd like to hear from you!
Please send us your
updates to:

obgynresidency@mcw.edu

PUBLICATIONS:

- Mutch D, Voulgari A, Chen XM, **Bradley WH**, Oaknin A, Perez Fidalgo JA, Montosa FG, Herraез AC, Holloway RW, Powell MA, Nowicka M, Schaefer G, Merchant M, Yan Y. Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer. *Cancer* 2024 Jun 01;130(11):1940-1951 PMID: 38288862 01/30/2024
- Uyar D, Michener CM, **Bishop E, Hopp E**, Simpson P, Zhang L, **Rader JS**, Rose PG, Mahdi HS, Debernardo R, Christian Q, **Bradley W**. Carboplatin, paclitaxel, and pembrolizumab followed by pembrolizumab maintenance for primary treatment of incompletely resected epithelial ovarian cancer. *Frontiers in Oncology* 2024;14 SCOPUS ID: 2-s2.0-85186485797 01/01/2024
- Mittal S, Kumar S, Gupta P, Singh M, Chaluvally-Raghavan P, Pradeep S**. Protocol for the isolation of tumor cell-derived extracellular vesicles followed by in vivo metastasis assessment in a murine ovarian cancer model (STAR Protocols 21 June 2024;5(2) SCOPUS ID: 2-s2.0-85187377383 06/21/2024
- Geethadevi A, Ku Z, Tsaih SW, Parashar D, Kadamberi IP, Xiong W, Deng H, George J, Kumar S, Mittal S, Zhang N, Pradeep S, An Z, Chaluvally-Raghavan P**. Blocking Oncostatin M receptor abrogates STAT3 mediated integrin signaling and overcomes chemoresistance in ovarian cancer. *NPJ Precis Oncol* 2024 Jun 05;8(1):127 PMID: 38839865 PMCID: PMC11153533 06/06/2024
- Mittal S, Kumar S, Gupta P, Singh M, Chaluvally-Raghavan P, Pradeep S**. Protocol for the isolation of tumor cell-derived extracellular vesicles followed by in vivo metastasis assessment in a murine ovarian cancer model. *STAR Protoc* 2024 Jun 21;5(2):102943 PMID: 38470912 PMCID: PMC10945248 03/12/2024
- Seitz V, **Davidson ERW**. Retained Tampon Fragment as an Unusual Cause of Vesicovaginal Fistula. *Obstet Gynecol* 2024 Jul 01;144(1):e1-e3 PMID: 38772038 05/21/2024
- Seitz V, Calata J, Mei L, **Davidson ERW** Racial Disparities in Sacral Neuromodulation for Idiopathic Fecal Incontinence. *Urogynecology (Phila)* 2024 May 02 PMID: 38710021 05/06/2024
- Luebke MC, **Davidson ERW**, Crotty BH, Fergestrom N, O'Connor RC, Schmitt E, Winn AN, Flynn KE, Neuner JM. Referral and Prescription Patterns for Female Patients With Urinary Incontinence. *Urogynecology (Phila)*. 2023 Oct 09 PMID: 37881958 10/26/2023
- Amies Oelschlager AME, **Gecsi K**, Rodriguez M. The Use of Cannabis Products for the Management of Pain Associated With Gynecologic Conditions. *Obstetrics and Gynecology* 1 July 2024;144(1):e24-e34 SCOPUS ID: 2-s2.0-85196707413 07/01/2024
- Summey RM**, Gornstein E, Decker B, Dougherty KC, **Rader JS, Hopp E**. Landscape of potential germline pathogenic variants in select cancer susceptibility genes in patients with adult-type ovarian granulosa cell tumors. *Cancer Med* 2024 Jun;13(12):e7340 PMID: 38898688 06/20/2024
- Moh M, Puzyrenko A, **Summey R, Rader JS**, Herrera Cano GE, Gavina JV, Rui H, Sun Y, **Hopp E**. Clinicopathologic Characteristics of a Single-institution Cohort of Ovarian Adult Granulosa Cell Tumors, With Biomarker and Therapeutic Implications Utilizing the Detection of Androgen, Estrogen, and Progesterone Hormone Receptor Expression by Immunohistochemistry. *Int J Gynecol Pathol* 2024 Mar 27 PMID: 38661526 04/25/2024
- Lambert E, Beroza A, Jaeke E, Szczgielski J, **Linton A, Dielentheis K**. Development and Trial of a Low-Cost, Simulation-Based Abortion Skills Training. *Wisconsin Medical Journal* Accepted for publication Spring 2024 03/01/2024
- van den Berg MC, Berg HF, Stokowy T, Hoivik EA, Woie K, Engerud H, **Ojesina AI**, Haldorsen IS, Trovik J, Bertelsen BI, Krakstad C, Halle MK. Expression patterns of mismatch repair proteins in cervical cancer uncover independent prognostic value of MSH-2. (*) Int J Gynecol Cancer* 2024 Jul 01;34(7):993-1000 PMID: 38950928 07/02/2024
- Rydze RT, Schoyer KD**. When to say when: optimal number of intrauterine insemination treatment cycles. *Fertil Steril* 2024 Jul;122(1):72-73 PMID: 38697238 05/03/2024

PUBLICATIONS CONT'D:

Kumari N, Kumari R, Dua A, **Singh M, Kumar R, Singh P, Duyar-Ayerdi S, Pradeep S, Ojesina AI, Kumar R.** From Gut to Hormones: Unraveling the Role of Gut Microbiota in (Phyto)Estrogen Modulation in Health and Disease. *Mol Nutr Food Res* 2024 Mar;68(6):e2300688 PMID: 38342595 02/12/2024

Emery SP, Lopa S, **Peterson E**, Jelin AC, Treadwell MC, Gebb J, Galan HL, Bergh E, Criebaum A, McLennan A, Lillegard J, Blumenfeld YJ. Prenatal Diagnosis of Fetal Aqueductal Stenosis: A Multicenter Prospective Observational Study through the North American Fetal Therapy Network. *Fetal Diagn Ther* 2024;51(3):216-224 PMID: 38320542 02/07/2024

CLINICAL UPDATES Cont'd

We've officially kicked off our **Perinatal Mobile Clinic**. With the Maternal Mobile Clinic, we bring important maternal health services directly to communities, making healthcare accessible and convenient for prenatal and postpartum (after birth) care.

Maternal Mobile Clinic Services:

- Prenatal exams
- Postpartum (after birth) exams
- Family planning
- Vaccine administration
- STI screening
- Postpartum (after birth) depression screening
- Access to psychiatric and psychologic services
- Access to lactation services
- Access to social services

The Maternal Mobile Clinic provides Convenience, Expertise, Accessibility, Compassionate Care, Innovation, and Community Connection.

CLINICAL UPDATES

The **Postpartum Patient Navigator Program** is a quality improvement effort to optimize patient engagement and care adherence throughout the fourth trimester. Since launching in October 2023, a total of 137 patients have enrolled with a continued engagement rate of approximately 78%. The next steps for our project team include assessing the efficacy, acceptability, and feasibility of expanding this program. Thank you to all the clinical team members who have supported this initiative so far. We are excited to continue exploring this program as a way to improve postpartum support for all Froedtert patients.

Project Team: Jackie Peebles, MD, Kristy Graettinger, MD, Alyssa Hernandez, DO (Project Manager), Natasha Griffin, M.Ed (Patient Navigator).

